Crossmark

VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma

Crossref DOI link: https://doi.org/10.1186/s12885-018-4442-2

Published Online: 2018-05-10

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Martini, Maurizio

de Pascalis, Ivana

D’Alessandris, Quintino Giorgio

Fiorentino, Vincenzo

Pierconti, Francesco

Marei, Hany El-Sayed

Ricci-Vitiani, Lucia

Pallini, Roberto

Larocca, Luigi Maria http://orcid.org/0000-0003-1739-4758
Funding

Funding for this research was provided by:

Associazione Italiana per la Ricerca sul Cancro (IG 2013 N.14574, IG 2013 N.14574)

Università Cattolica del Sacro Cuore (Linea D1, Linea D1, Linea D1)
License Information

Text and Data Mining valid from 2018-05-10
More Information

Article History

Received: 20 November 2017

Accepted: 26 April 2018

First Online: 10 May 2018

Ethics approval and consent to participate

: Ethical approval for study was provided by the ethics committee of Università Cattolica del Sacro Cuore, Roma (PROT. 1720-17). Written informed consent was obtained from all subjects or their guardians. Experiments involving animals were approved by the Ethical Committee of the Università Cattolica Sacro Cuore (UCSC), Rome (Pr. No. CESA/P/51/2012).The report does not present identifying images or other personal or clinical details of participants that compromise anonymity. Written informed consent was obtained from all subjects or their guardians.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.